Your browser doesn't support javascript.
loading
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy, Bjoern; Roemer, Margaretha G M; Stewart, Chip; Tan, Yuxiang; Abo, Ryan P; Zhang, Liye; Dunford, Andrew J; Meredith, David M; Thorner, Aaron R; Jordanova, Ekaterina S; Liu, Gang; Feuerhake, Friedrich; Ducar, Matthew D; Illerhaus, Gerald; Gusenleitner, Daniel; Linden, Erica A; Sun, Heather H; Homer, Heather; Aono, Miyuki; Pinkus, Geraldine S; Ligon, Azra H; Ligon, Keith L; Ferry, Judith A; Freeman, Gordon J; van Hummelen, Paul; Golub, Todd R; Getz, Gad; Rodig, Scott J; de Jong, Daphne; Monti, Stefano; Shipp, Margaret A.
Afiliação
  • Chapuy B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Roemer MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands;
  • Stewart C; Broad Institute, Cambridge, MA;
  • Tan Y; Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA;
  • Abo RP; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA;
  • Zhang L; Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA;
  • Dunford AJ; Broad Institute, Cambridge, MA;
  • Meredith DM; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • Thorner AR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA;
  • Jordanova ES; Center of Gynaecologic Oncology, VU University Medical Center, Amsterdam, The Netherlands;
  • Liu G; Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA;
  • Feuerhake F; Department of Pathology, Hannover Medical School, Hannover, Germany;
  • Ducar MD; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA;
  • Illerhaus G; Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany;
  • Gusenleitner D; Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA;
  • Linden EA; Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA;
  • Sun HH; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • Homer H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Aono M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Pinkus GS; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • Ligon AH; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • Ligon KL; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • Ferry JA; Department of Pathology, Massachusetts General Hospital, Boston, MA; and.
  • Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • van Hummelen P; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA;
  • Golub TR; Broad Institute, Cambridge, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Getz G; Broad Institute, Cambridge, MA; Department of Pathology, Massachusetts General Hospital, Boston, MA; and.
  • Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA;
  • de Jong D; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands;
  • Monti S; Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA;
  • Shipp MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
Blood ; 127(7): 869-81, 2016 Feb 18.
Article em En | MEDLINE | ID: mdl-26702065
Primary central nervous system lymphomas (PCNSLs) and primary testicular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior responses to current empiric treatment regimens. To identify targetable genetic features of PCNSL and PTL, we characterized their recurrent somatic mutations, chromosomal rearrangements, copy number alterations (CNAs), and associated driver genes, and compared these comprehensive genetic signatures to those of diffuse LBCL and primary mediastinal large B-cell lymphoma (PMBL). These studies identify unique combinations of genetic alterations in discrete LBCL subtypes and subtype-selective bases for targeted therapy. PCNSLs and PTLs frequently exhibit genomic instability, and near-uniform, often biallelic, CDKN2A loss with rare TP53 mutations. PCNSLs and PTLs also use multiple genetic mechanisms to target key genes and pathways and exhibit near-uniform oncogenic Toll-like receptor signaling as a result of MYD88 mutation and/or NFKBIZ amplification, frequent concurrent B-cell receptor pathway activation, and deregulation of BCL6. Of great interest, PCNSLs and PTLs also have frequent 9p24.1/PD-L1/PD-L2 CNAs and additional translocations of these loci, structural bases of immune evasion that are shared with PMBL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Translocação Genética / Linfoma Difuso de Grandes Células B / Neoplasias do Sistema Nervoso Central / Loci Gênicos / Proteínas de Neoplasias Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Translocação Genética / Linfoma Difuso de Grandes Células B / Neoplasias do Sistema Nervoso Central / Loci Gênicos / Proteínas de Neoplasias Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article